Altre lingue Xilio Therapeutics, Inc.

Azioni

XLO

US98422T1007

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,09 ^USD	+7,92%		-5,22%	+98,18%

01/04	Xilio Therapeutics, Inc. riporta i risultati degli utili per il quarto trimestre conclusosi il 31 dicembre 2023	CI
01/04	Xilio Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	19/04
Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results	01/04
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Sector Update: Health Care Stocks Slide Late Afternoon	01/04
Top Midday Gainers	01/04
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	01/04
Top Premarket Gainers	01/04
Xilio Shares Take Flight Premarket After Gilead Deal	28/03
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	28/03
Xilio Therapeutics : Corporate Update Call	28/03
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12	28/03
Xilio Therapeutics Plans Private Placement, Job Cuts	28/03
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program	28/03
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing	28/03
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc	28/03
Xilio Therapeutics, Inc. Plans Workforce Reduction	28/03
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202	28/03
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	28/03
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	28/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Xilio Therapeutics, Inc.

Azioni

XLO

US98422T1007

Altre lingue

Filtri